[PDF] Top 20 Inhaled Nitric Oxide in Preterm Infants: A Systematic Review

... immature preterm infants with hy- poxic respiratory failure, despite dif- ferences in disease ...term infants born at ⱕ 34 weeks’ ges- tation have been conducted in clini- cally diverse populations ... See full document

... that inhaled Nitric Oxide marginally reduced the incidence of death or CLD as well as severe brain damage in two stud- ies where iNO was used routinely for mildly sick preterm ...ill ... See full document

... on preterm infants’ health ...included preterm infants’ long-term neu- rodevelopment after discharge ...the preterm infants’ neurodevelopment during their NICU ...promoting ... See full document

... Previous systematic reviews and meta-analyses of inhaled corticosteroids for preterm infants have focused on specific indications and timing, al- though advancing understanding of the ... See full document

... This systematic review was conducted using an a priori published protocol submitted to the PROSPERO website (Registration number CRD42013005731) and reported according to the Preferred Reporting Items for ... See full document

... Nitric oxide, an important signaling molecule with multiple regulatory effects throughout the body, is an important tool for the treatment of full-term and late-preterm infants with persistent ... See full document

... European Inhaled Nitric Oxide Registry, which is funded through an educational grant from Linde Gas (Sweden); and Dr VanMeurs is the site principal investigator for the Ikaria Inc trial entitled ... See full document

... the systematic review was approved by the Cochrane Neonatal Review ...this review were as follows: the studies were randomized or quasi-randomized clinical trials, and the participants were ... See full document

... for preterm infants with PPHN treated with iNO, compared with infants treated with 100% ...these infants through the resolution of hypoxia during a critical phase of ... See full document

... in preterm infants occurs differently than in healthy term newborns [5], and preterm infants frequently have delayed and aberrant acquisition of the “normal” di- gestive ...in preterm ... See full document

... Recruiting centers (numbers in parentheses denote numbers of infants recruited): J. Staines and A. Hoyle, Ayrshire and Arran Hospital, Irvine, UK (1); A. Ryan and L. Bradfield, Erinville Hos- pital, Cork, Republic ... See full document

... that infants treated with iNO had statistically similar costs to those in the placebo group, because the cost of the drug was offset by a decrease in days of ventilation and hospital admis- ...For infants ... See full document

... for individual clinician judgment? Units can and should develop evidence-based guidelines for the use of iNO for preterm infants. Such guidelines could allow for its use in the presence of severe PH, but ... See full document

... in preterm infants of ⱕ 34 weeks’ gestation treated with iNO have been hampered by variation in measures used to assess neurodevelopmental status and the ages at which outcomes are measured and by the lack ... See full document

... in preterm infants of ⱕ 34 weeks’ gestation treated with iNO have been hampered by variation in measures used to assess neurodevelopmental status and the ages at which outcomes are measured and by the lack ... See full document

... first systematic review and meta-analysis [9] scrutinised five RCTs and found no beneficial effect on mortality or ventilator-free days, but given wide confidence intervals, the authors concluded that the ... See full document

... Exclusion criteria were ⬎ 14 days of postnatal age, life-threat- ening congenital malformations, structural heart disease other than patent ductus arteriosus or patent foramen ovale, congenital diaphragmatic hernia, or ... See full document

... To our knowledge, these results are derived from the largest number of preterm patients at high risk for de- veloping BPD reported to date. Most previously pub- lished studies reported serial results, without ... See full document

... oxide (NO) gas as an inhalational therapy for per- sistent pulmonary hypertension of the newborn (PPHN) was recently approved by the US Food and Drug Administration (FDA). Because iNO therapy has become adopted as ... See full document

... was review of the patients and iNO usage from the pre- vious ...periodic review of usage, patient outcomes, and compliance throughout the year at staff meetings and via e-mail communica- ... See full document